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Abstract
Purpose: COVID-19 has been associated with a dysregulated inflammatory response. Patients who have received solid-organ
transplants are more susceptible to infections in general due to the use of immunosuppressants. We investigated factors associated with mechanical ventilation and outcomes in solid-organ transplant recipients with COVID-19. Materials and Methods: We
conducted a retrospective cohort study of all solid-organ transplant recipients admitted with a diagnosis of COVID-19 in our 23hospital health system over a 1-month period. Descriptive statistics were used to describe hospital course and laboratory results
and bivariate comparisons were performed on variables to determine differences. Results: Twenty-two patients with solid-organ
transplants and COVID-19 were identified. Eight patients were admitted to the ICU, of which 7 were intubated. Admission values
of CRP (p ¼ 0.045) and N/L ratio (p ¼ 0.047) were associated with the need for mechanical ventilation. Seven patients (32%) died
during admission, including 86% (n ¼ 6) of patients who received mechanical ventilation. Conclusions: In solid-organ transplant
recipients with COVID-19, initial CRP and N/L ratio were associated with need for mechanical ventilation.
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Introduction
Coronavirus disease 2019 (COVID-19), caused by the Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),
continues to spread rapidly throughout the world. Much
remains unknown about the effects of SARS-Cov-2 on organ
function and the host response. The pathogenesis of COVID-19
induced organ dysfunction has been associated with evidence
of a dysregulated immune system.1 Given that organ transplant
recipients receive chronic immunosuppression, studying the
course of disease and factors that associate with illness severity
in this population may yield important observations. Literature
describing COVID-19 in this population has grown since the
pandemic began. This report will describe factors that are associated with critical illness in this population.
Reports from China and Spain first described a heart and renal
transplant recipient, respectively, with COVID-19 at the beginning of the outbreak.2,3 Since then, several series describe outcomes in solid-organ transplant recipients with COVID-19.4,5
A larger study found solid-organ transplant recipients had worse
outcomes with COVID-19 than non-transplanted patients, as has
been shown for other infectious diseases.6-8
In this study, we describe clinical characteristics and outcomes of a cohort of solid-organ transplant patients admitted to
a large health system during the first month of the COVID-19

outbreak in New York. We aim to determine which factors
present at admission were associated with need for mechanical
ventilation in the study population. We also seek to characterize alterations in lymphocyte count and kidney function in
individual patients during COVID-19 infection as compared
to their baseline values since these values are frequently abnormal in patients taking immunosuppressant medications or with
renal transplantation.
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Table 1. Baseline Characteristics of the Study Cohort.

Age (years, mean [median, STD])
Sex (n, %)
Female
Male
Organ Transplant Type (n, %)
Kidney
Liver
Lung
Heart
Months Since Transplant (mean, STD)
Immunosuppressive Agents (n, %)
Tacrolimus
Mycophenolate Mofetil
Prednisone
Cyclosporine

Total cohort (n ¼ 22)

Non-MV (n ¼ 15)

MV (n ¼ 7)

58.5 + 14.0

56.5 + 13.9

62.6 + 14.3

8 (36)
14 (64)

6 (40)
9 (60)

2 (29)
5 (71)

17 (77)
2 (9)
1 (5)
2 (9)
93 + 63)

11 (73)
2 (13)
0
2 (13)
89 + 55

6 (86)
0
1 (14)
0
102 + 82

21
20
15
1

Methods
We performed a retrospective cohort study of all patients age
18 years and older with a history of solid-organ transplantation
admitted to a Northwell Health hospital with a diagnosis of
COVID-19 during the month of March 2020. Data collection
closed after the last patient was discharged. Northwell is a 23hospital network in the New York metropolitan area composed
of community hospitals and tertiary care centers, with a total of
over 4,000 beds.
We queried the electronic medical record for patients with a
diagnosis of COVID-19 and history of solid-organ transplant
within the study dates. Demographic, clinical, laboratory, radiologic, and management data were collected using a standardized data collection form by one investigator (FM). Clinical
data collected included chief complaint, need for ICU admission, need for mechanical ventilation, length of stay, immunosuppressive medications, and COVID-19 specific treatments.
Laboratory values within 24 hours of admission recorded
included white blood cell count, absolute lymphocyte count
(ALC), absolute neutrophil count (ANC), neutrophil to lymphocyte ratio, creatinine, C-reactive protein (CRP), and ferritin.
These labs were routinely measured in patients with COVID19 at the study sites and were available for most patients. When
available, baseline serum creatinine and ALC at least 30 days
prior to admission and outside of an acute illness were also
recorded. If baseline values were not available, the individual
was excluded from that calculation. We defined acute kidney
injury (AKI) via the Kidney Disease Improving Global Outcomes (KDIGO) classification system, comparing admission
creatinine to a baseline level at least 30 days prior.9 For the
cohort requiring mechanical ventilation, Acute Physiology and
Chronic Health Evaluation II (APACHE-II) scores were calculated at time of ICU admission.10
We summarized continuous variables as means (standard
deviation) or median (interquartile range, IQR), as appropriate.

(95)
(91)
(68)
(5)

13
13
9
1

(87)
(87)
(60)
(7)

7 (100)
7 (100)
6 (86)
0

Categorical variables are reported as frequencies (percent). Student’s t-test was used to compare differences between groups’
baseline ALC and admission ALC, using each subject as a selfcontrol.11 Odds ratios and confidence intervals for mechanical
ventilation were calculated using logistic regression. A p-value
of 0.05 was considered significant. Regression were performed
with SAS: University-Edition (SAS Institute, Cary, NC).

Results
General Characteristics of Solid Organ Transplant
Recipients Admitted for COVID-19
Over the 1-month study period, 22 patients met inclusion criteria (Table 1). The majority (77%, n ¼ 17) were kidney transplant recipients. The remaining patients were recipients of liver
(9%, n ¼ 2), heart (9%, n ¼ 2), and lung (5%, n ¼ 1) transplants. Average time since transplantation was 93 + 63
months. Presenting symptoms included fever (77%, n ¼ 17),
cough (50%, n ¼ 11), dyspnea (32%, n ¼ 7), and diarrhea
(18%, n ¼ 4). Thirty-six percent (n ¼ 8) patients were admitted
to the ICU and the remaining 64% (n ¼ 14) were managed on the
general inpatient floors. Indication for ICU admission in all
patients was hypoxemic respiratory failure. Seven (32%) patients
required mechanical ventilation. The median APACHE-II score
of patients in our cohort requiring mechanical ventilation was
27 (IQR 21-34).
Of the total cohort, 32% (n ¼ 7) died and 68% (n ¼ 15)
survived to hospital discharge. Average length of stay (LOS)
for survivors was 11.1 + 6.7 days (Table 2). Six of 7 patients
who died were kidney transplant recipients and one had
received a lung transplant. Five of 7 mortalities were male
(71%). All were prescribed tacrolimus and a mycophenolic
acid derivative, and 6 of 7 were prescribed prednisone for
immunosuppression. Additional information on patients requiring mechanical ventilation can be found in Table 3.
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Table 2. Clinical Findings and Treatment Course of the Study Cohort.
Total cohort (n ¼ 22)
Presenting Signs and Symptoms (n, %)
Fever
Cough
Dyspnea
Diarrhea
Hypoxemia
APACHE-II (median, IQR)
ICU Admission (n, %)
COVID-19 Specific Treatments (n, %)
Hydroxychloroquine
Azithromycin
Corticosteroids
Tocilizumab
Anakinra
Length of Stay (days, mean, SD)1
Vital Status (n, %)
Alive
Deceased
1

Non-MV (n ¼ 15)

17 (77)
11 (50)
7 (32)
4 (18)
16 (73)

12
9
4
4
9

8 (36)

MV (n ¼ 7)

80)
(60)
(27)
(27)
(60)

5 (71)
2 (29)
3 (43)
0
7 (100)
27 (21-34)
7 (100)

1 (7)

17 (77)
10 (45)
3 (14)
1 (5)
1 (5)
11.1 + 6.7

11
4
2
0
1

15 (68)
7 (32)

(73)
(27)
(13)

6 (86)
6 (86)
1 (14)
1 (14)
0

(7)

14 (93)
1 (7)

1 (14)
6 (86)

Calculated for patients discharged alive.

Table 3. Specific Treatment and Clinical Course Data for the 7 Patients Who Required Mechanical Ventilation.
Age

Sex

Organ transplanted

40
80
57
56
56
77
72

M
M
M
M
F
M
F

Kidney
Kidney
Kidney
Kidney
Kidney
Kidney
Lung

Months since transplant
105
168
12
244
36
46
106

Immunosuppression
MMF,
MMF,
MMF,
MMF,
MMF,
MMF,
MMF,

tacrolimus,
tacrolimus
tacrolimus,
tacrolimus,
tacrolimus,
tacrolimus,
tacrolimus,

prednisone
prednisone
prednisone
prednisone
prednisone
prednisone

LOS (days)

ICU LOS (days)

Outcome

43
20
14
7
9
17
54

37
14
14
4
2
6
44

Died
Survived
Died
Died
Died
Died
Died

LOS, Length of Stay; ICU, Intensive Care Unit; MMF, Mycophenolate mofetil.

Immunosuppression Regimens
All patients in our cohort were managed with immunosuppressive medications prior to hospital admission (Table 1). The
most common immunosuppressants prior to admission were
tacrolimus (95%, n ¼ 21), mycophenolic acid derivatives
(91%, n ¼ 20) and prednisone (68%, n ¼ 15). Mycophenolic
acid derivatives were discontinued on all patients upon admission. Tacrolimus was discontinued in 10% (n ¼ 2 of 21) and
cyclosporine was discontinued in a liver-transplant patient for
whom it was the sole immunosuppressant. All 14 patients on
corticosteroids prior to admission were continued on corticosteroids at their home dose for the duration of admission. No
acute episodes of rejection were treated during hospitalization
for COVID-19.

infection as compared to baseline (0.83 + 0.47 vs 1.46 + 0.73,
p < 0.001).
We compared patients requiring mechanical ventilation to
those not requiring mechanical ventilation, to determine if specific laboratory abnormalities present on admission were associated with eventual need for mechanical ventilation. For every
1-unit increase in the N/L, the odds of eventual mechanical
ventilation increased by 24% (OR 1.24; 95% CI 1.01-1.52,
p ¼ 0.047). For every 1mg/dL increase in CRP at time of
admission to the hospital, the odds of eventual mechanical
ventilation increased by 18% (OR 1.18; 95% CI: 1.01-1.39,
p ¼ 0.045) (Figure 1). There was no association with admission
WBC or ferritin and mechanical ventilation (Table 4).

Acute Kidney Injury
Laboratory Abnormalities
We compared ALC in solid organ transplant recipients during
their COVID-19 infection to their baseline ALC (data available
for 68%, n ¼ 15). ALC was significantly lower during COVID-19

Rate of AKI in the total cohort of patients was 37% (n ¼ 7, data
available for 19 subjects). In patients requiring mechanical
ventilation, the rate of AKI during their ICU stay was 60%
(n ¼ 3, data available for 5 of 7 patients).
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Figure 1. A plot of the admission CRP (mg/dL) level against the admission N/L ratio for patients who required and did not require mechanical
ventilation.
Table 4. Laboratory Results of Patients on Admission.a
Total Cohort (n ¼ 22)
Laboratory Values (mean, SD)
Leukocyte Counts
White Blood Cell Count (n ¼ 22)
5.9 + 2.5
ANC (K/mL)
4.4 + 2.3
ALC (K/mL)
0.82 + 0.4
N:L
7.5 + 6.4
CRP
Admission CRP (mg/dL)
9.6 + 8.5 (n ¼ 20)
Ferritin
Admission ferritin (ng/mL)
1327 + 1672 (n ¼ 19)
Creatinine
Admission Creatinine (mg/dL)
1.82 + 1.07
AKI on Admission (n, %)
7 (37%, n ¼ 19)
a

Non-MV (n ¼ 15)

MV (n ¼ 7)

OR (CI, p-value)

Reference Range

5.7 + 2.1
4.0 + 1.6
0.91 + 0.4
5.3 + 3.3

5.4 + 3.4
5.4 + 3.2
0.62 + 0.4
12.2 + 8.9

1.10 (0.77-1.58, 0.59)

3.8-10.5 K/mL
1.8-7.4 K/mL
1.0-3.3 K/mL

6.33 + 6.5 (n ¼ 13)

15.7 + 8.7

1.18 (1.004-1.387, 0.045)

1160 + 1689 (n ¼ 12)

1612 + 1733

1.72 + 1.00
4 (29%, n ¼ 14)

2.06 + 1.26
3 (60%, n ¼ 5)

1.24 (1.003-1.519, 0.047)
<5.0 mg/L
30-400 ng/mL
1.00 (1.00-1.00, 0.57)
0.5-1.3 mg/dL

Odds ratios are for mechanical ventilation.

COVID-19 Specific Therapies
Hydroxychloroquine was administered to 77% (n ¼ 17). Azithromycin was given to 41% (n ¼ 9), 8 of whom also received
hydroxychloroquine. Corticosteroids were given to 14% (n ¼
3). One patient (5%) received tocilizumab and one patient (5%)
received anakinra.

Discussion
We found typical features of COVID-19 presentation in our
study cohort, including fever, cough, dyspnea, and lymphopenia. This is in agreement with findings of other studies of
COVID-19 in solid organ transplant recipients.4,6 The neutrophil to lymphocyte ratio has previously been reported as a
significant predictor of outcomes in COVID-19.12 We found

that this value was also associated with the need for mechanical
ventilation in solid-organ transplant recipients.
Lymphopenia has previously been associated with mortality
in solid-organ transplant recipients and in general populations
with COVID-19.7,12-14 It is unclear how the lymphopenia and
T-cell dysfunction of immunosuppressed solid-organ transplant recipients affects the clinical course of COVID-19.15,16
We found reductions in ALC on admission with COVID-19 in
patients with already impaired lymphocytes. Admission creatinine was higher in patients who required mechanical ventilation, this is similar to a recent large review of outcomes in
COVID-19 in patients with solid organ transplants.17
CRP has been correlated to more severe illness in general
adult studies with sepsis and COVID-19, specifically.18,19 We
found CRP correlated with need for mechanical ventilation in
our cohort. The values we report for CRP in our solid organ
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transplant recipient population are similar to levels reported in
a general cohort of critically ill Chinese patients with COVID19 ¼ (average CRP 10.5 + 1.27 mg/dL), as well as reported
critically ill solid-organ transplant patients in New York.6,20
Given the small size of our cohort, we are unable to stratify
based on type of organ transplantation or immunosuppressant
regimen, though there may be differential effects of COVID-19
based on the transplanted organ. We report only one lung transplant recipient in our cohort and no pancreas or small intestine
transplant recipients, though these are less common.
Future studies may determine if N/L and CRP have predictive
value in the early identification of patients at risk for a more
severe COVID-19 phenotype and subsequently most likely to
benefit from COVID-19-specific interventions. This is especially valuable today given emerging evidence that convalescent
plasma, remdesivir, and glucocorticoids may benefit patients
with COVID-19.21-23 Identifying patients at risk of decline during admission could help direct future scarce therapies, better
allocate resources, and inform patients and clinicians in shared
decision making and prognosis. Much is still unknown regarding
different immune responses to COVID-19 that may drive severity of infection. Patients with solid-organ transplants and associated T-cell suppression may have responses different from the
general population that put them at different risk of developing
severe disease. There is evidence that the CRP level can predict
responsiveness to corticosteroids in a general population of hospitalized patients with COVID-19.24
Limitations of our study include its retrospective design and
small sample size due to the recent emergences of COVID-19.
The study’s descriptive nature precludes causal inference. Our
method of identifying patients relied on electronic medical
record capture of both COVID-19 and history of transplantation. As such, some transplant patients may not have been
included in the study due to unknown errors in diagnostic coding. Despite these limitations, the association between elevations in N/L and CRP and need for mechanical ventilation
reflect hypothesis generation that may warrant further exploration in solid organ transplant patients with COVID-19.

Conclusions
Initial abnormalities in the CRP level and neutrophil to lymphocyte ratio are associated with subsequent mechanical ventilation in solid-organ transplant recipients.
Abbreviations
ALC, Absolute lymphocyte count; ANC, Absolute neutrophil count;
APACHE-II, Acute Physiology Age and Chronic Health Evaluation
II; ARDS, Acute Respiratory Distress Syndrome; COVID-19, Coronavirus Disease 2019; ICU, Intensive Care Unit; IQR, Interquartile
range; DIGO, Kidney Disease Improving Global Outcomes; N/L,
Neutrophil to lymphocyte ratio; SARS-Cov-2, Severe Acute Respiratory Syndrome Coronavirus 2.
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